{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"Best overall response was defined as stringent complete response + complete response + very good partial response + partial response following treatment with AUTO2. Response Criteria Per IMWG Consensus Recommendations","groups":[{"description":"Relapsed or refractory myeloma patients.","id":"OG000","title":"AUTO2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All patients who received at least 1 dose (complete or partial) of AUTO2 therapy in Phase I of the study were included in this analysis. No patients were enrolled in Phase II as the study was early terminated in Phase I. 2 patients were retreated; their best overall response is presented for this endpoint","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Number of Infused Patients With Best Overall Response","type":"PRIMARY","unitOfMeasure":"Participants"}